[go: up one dir, main page]

EP3967323A3 - Hiv vaccine - Google Patents

Hiv vaccine Download PDF

Info

Publication number
EP3967323A3
EP3967323A3 EP21176262.0A EP21176262A EP3967323A3 EP 3967323 A3 EP3967323 A3 EP 3967323A3 EP 21176262 A EP21176262 A EP 21176262A EP 3967323 A3 EP3967323 A3 EP 3967323A3
Authority
EP
European Patent Office
Prior art keywords
hiv
hiv vaccine
relates
present
novel combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21176262.0A
Other languages
German (de)
French (fr)
Other versions
EP3967323A2 (en
Inventor
Birger SØRENSEN
Mats ÖKVIST
Arnt Ove HOVDEN
Maja Sommerfelt GRØNVOLD
Lars HØIE
Anker LUNDEMOSE
Vidar Wendel Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionor Immuno AS
Original Assignee
Bionor Immuno AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionor Immuno AS filed Critical Bionor Immuno AS
Publication of EP3967323A2 publication Critical patent/EP3967323A2/en
Publication of EP3967323A3 publication Critical patent/EP3967323A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.
EP21176262.0A 2012-06-06 2013-06-06 Hiv vaccine Withdrawn EP3967323A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261656242P 2012-06-06 2012-06-06
US201361768905P 2013-02-25 2013-02-25
PCT/EP2013/061750 WO2013182660A1 (en) 2012-06-06 2013-06-06 Hiv vaccine
EP13730828.4A EP2858667A1 (en) 2012-06-06 2013-06-06 Hiv vaccine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP13730828.4A Division EP2858667A1 (en) 2012-06-06 2013-06-06 Hiv vaccine

Publications (2)

Publication Number Publication Date
EP3967323A2 EP3967323A2 (en) 2022-03-16
EP3967323A3 true EP3967323A3 (en) 2022-05-04

Family

ID=48577074

Family Applications (3)

Application Number Title Priority Date Filing Date
EP21176262.0A Withdrawn EP3967323A3 (en) 2012-06-06 2013-06-06 Hiv vaccine
EP13730828.4A Ceased EP2858667A1 (en) 2012-06-06 2013-06-06 Hiv vaccine
EP13727203.5A Withdrawn EP2858665A1 (en) 2012-06-06 2013-06-06 Vaccine

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP13730828.4A Ceased EP2858667A1 (en) 2012-06-06 2013-06-06 Hiv vaccine
EP13727203.5A Withdrawn EP2858665A1 (en) 2012-06-06 2013-06-06 Vaccine

Country Status (13)

Country Link
US (2) US20150174235A1 (en)
EP (3) EP3967323A3 (en)
JP (1) JP2015520179A (en)
KR (1) KR20150029678A (en)
CN (1) CN104717974A (en)
AU (2) AU2013273481B2 (en)
CA (2) CA2874936A1 (en)
EA (1) EA201492260A1 (en)
HK (3) HK1207829A1 (en)
IL (1) IL235890A0 (en)
IN (1) IN2014KN02774A (en)
MX (1) MX2014014668A (en)
WO (2) WO2013182662A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
JP6382831B2 (en) 2012-11-30 2018-08-29 サンフォード−バーンハム メディカル リサーチ インスティテュート Antagonists of apoptosis inhibitory protein (IAP)
CN104069106A (en) * 2013-03-27 2014-10-01 南通瑞思医药技术有限公司 Application of benzamide compound in preparation of medicine for activating latent human immunodeficiency virus
WO2015086738A2 (en) * 2013-12-11 2015-06-18 Bionor Immuno As Hiv vaccine
EP3082799B1 (en) * 2013-12-17 2021-04-28 Versitech Limited Use of isoflavones for the treatment of retroviral infection
EP3099322A1 (en) * 2014-01-27 2016-12-07 Bionor Immuno AS Method for the vaccination against hiv
CA2936335A1 (en) * 2014-01-27 2015-07-30 Bionor Immuno As Dosage regimen for hiv vaccine
WO2015110659A1 (en) * 2014-01-27 2015-07-30 Bionor Immuno As Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
US10300074B2 (en) * 2014-06-04 2019-05-28 Sanford Burnham Prebys Medical Discovery Institute Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
WO2016005508A1 (en) * 2014-07-11 2016-01-14 Bionor Immuno As Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
EA201790024A1 (en) 2014-07-11 2017-07-31 Джилид Сайэнс, Инк. MODULATORS OF TOLL-LIKE RECEPTORS FOR HIV TREATMENT
US9732119B2 (en) * 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) * 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) * 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
CN105878231A (en) * 2015-01-26 2016-08-24 复旦大学 Application of flavonoid compounds in preparing anti-HIV-latency therapeutic drugs
US20160222060A1 (en) * 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
WO2016134202A1 (en) * 2015-02-20 2016-08-25 The Johns Hopkins University Drug combinations for the treatment of hiv
WO2016177833A1 (en) * 2015-05-04 2016-11-10 Bionor Immuno As Dosage regimen for hiv vaccine
EP3319631A4 (en) * 2015-07-08 2019-01-09 American Gene Technologies International Inc. PRE IMMUNIZATION AND IMMUNOTHERAPY OF HIV
WO2017060524A1 (en) * 2015-10-09 2017-04-13 4Sc Ag (e)-n-(2-aminophenyl)-3-(1-((4-(1-methyl-1h-pyrazol-4-yl)phenyl)sulfonyl)-1h-pyrrol-3-yl)acrylamide for the treatment of latent viral infections
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
CA3011529A1 (en) 2016-01-15 2017-07-20 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta t-cells
US10888613B2 (en) 2016-02-08 2021-01-12 American Gene Technologies International Inc. Method of producing cells resistant to HIV infection
US10143746B2 (en) * 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
ES2911448T3 (en) 2016-03-09 2022-05-19 American Gene Tech Int Inc Combined Vectors and Methods for Cancer Treatment
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
EP3468617A4 (en) 2016-06-08 2020-01-22 American Gene Technologies International Inc. SYSTEM FOR THE NON-INTEGRAL VIRAL ISSUE AND PROCEDURE RELATING TO IT
IL300730A (en) 2016-07-08 2023-04-01 American Gene Tech Int Inc Hiv pre-immunization and immunotherapy
JP7176756B2 (en) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Viral vectors for treating Parkinson's disease
CN106563124A (en) * 2016-10-19 2017-04-19 广西大学 Application of lipoic acid as vaccine adjuvant
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
KR20220034736A (en) 2019-05-31 2022-03-18 비락타 서브시디어리 인크. How to use histone deacetylase inhibitors to treat virus-associated cancer
CN110423723A (en) * 2019-07-18 2019-11-08 南方医科大学南方医院 A kind of construction method of peripheral blood B cell system and its application
JP2023510737A (en) 2020-01-06 2023-03-15 ブリストル－マイヤーズ スクイブ カンパニー Immunomodulator
CN115362166A (en) 2020-03-30 2022-11-18 百时美施贵宝公司 Immunomodulator
EP4313046A1 (en) * 2021-03-31 2024-02-07 Celleron Therapeutics Limited Vaccine adjuvant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052040A1 (en) * 1999-03-04 2000-09-08 Bionor Immuno As Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
WO2011000962A2 (en) * 2009-07-03 2011-01-06 Bionor Immuno As Novel therapeutic and diagnostic means

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (en) 1982-08-30 1984-03-02 Musashi Eng Kk Paper leaf discriminating method
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
JPS62164696A (en) 1986-01-06 1987-07-21 エフ．ホフマン　―　ラ　ロシュ　アーゲー Expression of HTLV-3gag gene
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4925784A (en) 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
GB8629116D0 (en) 1986-12-05 1987-01-14 Hoffmann La Roche Env/gag polypeptides
EP0356007A3 (en) 1988-07-22 1991-07-03 Medical Research Council Antigenic determinants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
SE468168B (en) 1990-02-20 1992-11-16 Replico Medical Ab HIV-1, P24 PEPTIDES, DIAGNOSTIC ANTIGENS AND PROCEDURES FOR DIFFERENTIAL DIAGNOSTICS OF PRELIMINARY HIV-1 POSITIVE SERUM TESTS
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (en) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
DE69233204T2 (en) 1991-12-13 2004-07-15 Xoma Corp., Berkeley METHOD AND MATERIALS FOR THE PRODUCTION OF MODIFIED VARIABLE ANTIBODY DOMAINS AND THEIR THERAPEUTIC USE
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5697151A (en) 1995-08-07 1997-12-16 General Electric Company Method for repairing partitions of a turbine diaphragm
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
PL195916B1 (en) 1996-07-24 2007-11-30 Celgene Corp 1-oxoisoindoline and 1,3-dioxoisoindoline substituted optic isomers, pharmaceutical compositions containing them and application thereof
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
AU729247B2 (en) 1996-08-12 2001-01-25 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
JP4695259B2 (en) 1998-03-16 2011-06-08 セルジーン コーポレイション 2- (2,6-Dioxopiperidin-3-yl) isoindoline derivatives, their preparation and their use as inflammatory cytokine inhibitors
DE69918146T2 (en) 1998-10-05 2005-07-07 Pharmexa A/S METHOD FOR THERAPEUTIC VACCINATION
AU771015B2 (en) 1999-03-18 2004-03-11 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
ES2321584T3 (en) * 2000-07-17 2009-06-09 Astellas Pharma Inc. FK228 REDUCED AND ITS USE.
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2007534631A (en) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ Laminin-5γ2 binding peptides, related compositions and uses thereof
EP1928492B1 (en) 2005-09-01 2011-02-23 Celgene Corporation Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
CN101626763A (en) * 2006-12-06 2010-01-13 北海道公立大学法人札幌医科大学 Cellular immune enhancement using Histone Deacetylase (HDAC) inhibitors
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
WO2012051492A2 (en) 2010-10-14 2012-04-19 University Of Georgia Research Foundation, Inc. Compounds and methods for inhibiting hiv latency
CN103282375B (en) 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 peptide scaffold design
BR112013017488A2 (en) 2011-01-06 2017-08-01 Bionor Immuno As multimeric and monomeric immunogenic peptides
JP6208667B2 (en) 2011-10-03 2017-10-04 ユニベルシテ リブレ デ ブリュッセル Reactivation of HIV-1 gene expression to treat persistent HIV infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052040A1 (en) * 1999-03-04 2000-09-08 Bionor Immuno As Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
WO2011000962A2 (en) * 2009-07-03 2011-01-06 Bionor Immuno As Novel therapeutic and diagnostic means

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIONOR: "Vacc-4x Therapeutic HIV Vaccine Linked to Lower Viral Load in Phase IIb Study", 21 February 2012 (2012-02-21), pages 1 - 3, XP002714816, Retrieved from the Internet <URL:http://www.hivandhepatitis.com/hiv-prevention/hiv-vaccines/3465-vacc-4x-therapeutic-hiv-vaccine-linked-to-lower-viral-load-in-phase-iib-study> [retrieved on 20131015] *

Also Published As

Publication number Publication date
WO2013182662A1 (en) 2013-12-12
CA2874936A1 (en) 2013-12-12
US10335482B2 (en) 2019-07-02
HK1207829A1 (en) 2016-02-12
HK1208150A1 (en) 2016-02-26
WO2013182660A1 (en) 2013-12-12
EP3967323A2 (en) 2022-03-16
EA201492260A1 (en) 2015-08-31
US20150132255A1 (en) 2015-05-14
KR20150029678A (en) 2015-03-18
IL235890A0 (en) 2015-01-29
MX2014014668A (en) 2015-03-19
AU2013273481A1 (en) 2014-12-18
CN104717974A (en) 2015-06-17
EP2858667A1 (en) 2015-04-15
AU2013273481B2 (en) 2018-04-05
IN2014KN02774A (en) 2015-05-08
HK1207967A1 (en) 2016-02-19
CA2875624A1 (en) 2013-12-12
US20150174235A1 (en) 2015-06-25
EP2858665A1 (en) 2015-04-15
JP2015520179A (en) 2015-07-16
AU2013273483A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
EP3967323A3 (en) Hiv vaccine
MX388743B (en) OLIGONUCLEOTIDE-PEPTIDE CONJUGATES.
WO2016037154A8 (en) Recombinant hiv-1 envelope proteins and their use
WO2016070166A3 (en) Messenger una molecules and uses thereof
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
EA201591027A1 (en) POLYCYCLIC CARBAMOILPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATIONS
BR112013012555A2 (en) Immunogenic peptides for use in the prevention and / or treatment of infectious diseases, autoimmune diseases, immune responses to allopaths, allergic diseases, tumors, graft rejection, and immune responses against viral vectors used for gene therapy or gene vaccination.
WO2008118849A3 (en) Hiv-1 protease inhibitors
EA201591287A1 (en) VACCINES CONTAINING STABILIZED TRIMMERS OF THE HUMAN IMMUNODEFICIENCY VIRUS VIRUS, AND METHODS OF THEIR USE
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2013006688A3 (en) N-terminal deleted gp120 immunogens
EP2841107A4 (en) HIV-TARGETING CYTOTOXIC MEDICINAL PRODUCTION MOLECULE (CDM-H), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE THEREOF
EA201300132A1 (en) PHARMACEUTICAL COMPOSITION AND METHODS OF TREATMENT AND PREVENTION OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV
EA201290956A1 (en) VACCINE AGAINST HIV
EA201171186A1 (en) SOKRISTALL ETRAVIRIN AND NICOTINAMIDE
PH12017500450A1 (en) Flavivirus virus like particle
WO2012047267A3 (en) Polyvalent immunogen
WO2010041241A3 (en) Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
WO2015086738A3 (en) Hiv vaccine
MX347911B (en) Bvdv vaccine.
EP2678031A4 (en) GP96-IG-VIS / COMBINED HIV OF CELL ORIGIN, RECOMBINANT GP120 PROTEIN VACCINATION FOR SCREEN PROTECTION / HIV
WO2015043566A8 (en) Cyclic amyloid-beta-binding peptides and the use thereof
WO2012138911A3 (en) Conjugates of anti-hiv drugs and somatostatin analogs
WO2014025749A3 (en) Small molecule inhibitors of viral protein interactions with human t-rna
EP2632942A4 (en) Recombinant envelope protein of human immunodeficiency virus (hiv) and vaccine containing the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 2858667

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/19 20060101ALI20220329BHEP

Ipc: A61K 31/00 20060101ALI20220329BHEP

Ipc: A61K 39/21 20060101ALI20220329BHEP

Ipc: A61K 39/00 20060101AFI20220329BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221105